Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008933 | 1.00 | ABCB1 (0.43) | ABCB1KCNA5KCNE1KCNQ1IDO1 | |
| SCHEMBL2008931 | 1.00 | ABCB1 (0.43) | ABCB1KCNA5KCNE1KCNQ1IDO1 | |
| SCHEMBL2007814 | 0.86 | ABCB1 (0.51) | ABCB1KCNA5IDO1CYP3A4CYP2D6 | |
| SCHEMBL2889446 | 0.86 | ABCB1 (0.51) | ABCB1KCNA5IDO1CYP3A4CYP2D6 | |
| SCHEMBL2875838 | 0.84 | KCNA5 (0.42) | ABCB1KCNA5 | |
| SCHEMBL2875841 | 0.84 | KCNA5 (0.42) | ABCB1KCNA5 | |
| SCHEMBL2012412 | 0.83 | KCNA5 (0.39) | ABCB1KCNA5 | |
| SCHEMBL2012416 | 0.83 | KCNA5 (0.39) | ABCB1KCNA5 | |
| SCHEMBL13476129 | 0.83 | ABCB1 (0.48) | ABCB1KCNA5IDO1 | |
| SCHEMBL12641484 | 0.82 | KCNA5 (0.39) | ABCB1KCNA5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | ABCB1 580/4885KCNA5 67/4885KCNE1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.